pH and Oxygen Optical Sensors:

Optical pH and dissolved oxygen (DO) sensors represent a major advancement in single-use bioprocessing, shifting the industry away from traditional electrochemical probes and eliminating the contamination risks and manual recalibration bottlenecks of these probes. The ADVA X3® platform utilizes solid-state sensors that operate non-invasively through clear vessel walls by utilizing specialized fluorescent indicator patches embedded directly within the fluid path to monitor pH and dissolved oxygen (DO) in real time. When excited by a specific wavelength of light from an external optical reader, the patch emits a fluorescent signal; the presence of oxygen dynamically quenches this fluorescence intensity and lifetime, while pH levels alter the emission spectrum of the protonated and deprotonated dye molecules. By eliminating physical, fluid-contacting connections, membrane polarization times, and the sensor drift common with traditional electrodes, optical pH and DO sensors provide highly stable, continuous, and contamination-free measurements that is fed directly into the CAMP® adaptive control system, enabling AI-driven real-time process adjustments to preserve the strict homeostatic microenvironment required for optimal cell quality and maximum yield.

Metabolites Sensor:

The ADVA X3® continuous, non-invasive electrochemical sensor network tracks glucose, lactate, glutamine, and glutamate to deliver a complete picture of cellular bioenergetics and functional health. Glucose consumption rate reflects the culture′;s immediate kinetic energy demand, growth phase, and metabolic activity. Accompanying Lactate accumulation acts as a critical readout of respiratory efficiency, toxic byproduct accumulation, and environmental stress, warning the system of anaerobic shifts that could lead to media acidification and compromised cell quality. Glutamine is the secondary essential carbon and nitrogen source for rapidly dividing cells, feeding directly into the TCA cycle via Glutaminolysis. Continuous tracking of glutamine depletion directly reflects mitochondrial health, protein synthesis rates, and proliferative capacity. Meanwhile, the accumulation or conversion of Glutamate acts as a sensitive sensor-driven indicator of cellular stress, oxidative protection, and nutrient utilization efficiency.

By monitoring these four specific coupled metabolites simultaneously, the CAMP® smart core receives an instantaneous, high-fidelity map of both viable cell density and metabolic fitness. This allows the platform to dynamically adjust closed-loop perfusion and feed rates—keeping advanced therapeutic cultures in a pristine, homeostatic state without a single manual intervention.

Manual Disadvantages:

In advanced cell and gene therapy manufacturing, traditional manual systems rely heavily on human operator intervention, which introduces significant structural, biological, and regulatory disadvantages:

• Elevated Contamination Risks: Every manual intervention, open-vessel transfer, or offline physical sampling step introduces a direct pathway for microbial or environmental contaminants to compromise the sterile boundary. Even within high-grade cleanrooms, human operators remain the primary source of particulate and biological shedding.

• Run-to-Run Variability: Human operators—even highly skilled technicians—introduce subtle physical variations across different shifts and handoffs. Minor deviations in pipetting speeds, fluid transfers, agitation timing, and temperature fluctuations alter the delicate microenvironment, leading to inconsistent cell yield, differentiation states, and final product quality.

• Traceability & Compliance Bottlenecks: Manual data logging is highly prone to recording errors, transcript omissions, and delayed documentation. In a cGMP environment, the lack of real-time, automated software monitoring makes it exceptionally difficult to construct secure, unalterable Electronic Batch Records (EBRs), increasing audit vulnerability under FDA 21 CFR Part 11 guidelines.

• Prohibitive Labor Costs & Scalability Limits: Manual manufacturing relies on small-scale, labor-intensive vessel systems (2D tissue flasks) that cannot be scaled efficiently. Scaling out requires a linear, cost-prohibitive increase in cleanroom footprint, specialized staffing, and round-the-clock physical monitoring, making life-saving autologous therapies economically unsustainable for broad commercial distribution.
  
  The ADVA X3® platform, powered by automated CAMP® technology, completely neutralizes these legacy bottlenecks. By transitioning from manual, open manipulations to a fully automated, closed, single-use system, the platform removes the human element from the critical path entirely. The result is a highly predictable, repeatable manufacturing process that secures uniform, high-yield therapeutic expansions and automatically compiles audit-ready EBRs - all while operating in lower-cost, decentralized ISO 7/8 environments.

Continuous Process

The ADVA X3® platform operates as a Continuous Process. It transitions cell therapy manufacturing from traditional, intervention-heavy batch methods to a truly simple flow. Using integrated, non-invasive optical and electrochemical biosensors embedded within its single-use kit, the platform continuously monitors 14 critical parameters online—specifically tracking glucose and lactate metabolic consumption in real time. This high-fidelity data feeds directly into the proprietary CAMP® smart core, which automatically and dynamically adjusts perfusion, feeding, and waste removal rates to match the cells′; immediate physiological needs. Throughout this cycle, the core chamber "The Cone" geometry maintains a continuous, impeller-free Shearless Flow, ensuring uniform media circulation and gas exchange without risking mechanical damage to fragile cell phenotypes. Finally, the run concludes with automated, centrifugation-free fluidic washing, keeping the entire expansion and harvest pipeline in a gentle, uninterrupted, and completely closed homeostatic state.

Scale Up:

In ADVA X3®, Scale-up is entirely managed within a single, continuous, closed-loop run. Our intelligent CAMP® technology dynamically monitors metabolic consumption across 14 continuous online parameters (including glucose and lactate). As cell density increases, the system automatically scales perfusion and feeding rates in real time. As the ADVA X3® utilizes a unique, bottom-to-top Shearless flow design, the physical forces on the expanding cells remain perfectly uniform, allowing massive cell yields to be achieved in a single batch without manual intervention or structural cell damage.

Scale Up:

The ADVA X3® platform is engineered specifically to maximize the efficiency of horizontal scale-out. The fact that each single-use kit is entirely closed and automated, the platform eliminates the need for multi-million dollar, centralized Grade A/B cleanroom infrastructure, allowing parallel scale-out units to operate safely within lower-cost, decentralized ISO 7 or ISO 8 environments. Furthermore, because the platform utilizes identical sensor infrastructure and software control loops across both R&D and clinical-scale units, transitioning a process from early-stage development to multi-unit commercial scale-out requires zero process redevelopment. This standardized, automated replication bypasses legacy technology-transfer bottlenecks, compressing clinical validation timelines by months and bringing point-of-care manufacturing directly to the clinical site.

Remote Access

The ADVA X3® platform incorporates secure, remote-access monitoring capabilities that enable operators to oversee decentralized manufacturing units from a single control point. This remote architecture seamlessly transmits encrypted data packets directly from the active culture environment, facilitating the real-time compilation of automated, tamper-proof Electronic Batch Records (EBR). By providing continuous process visibility without requiring physical intervention on the floor, this remote system ensures robust data integrity compliant with FDA 21 CFR Part 11 parameters while maintaining uniform, parallel scale-out execution across lower-cost ISO 7 or ISO 8 environments.